ES2738315T3 - Composiciones terapéuticas y procedimientos que implican la transfección de ARNm - Google Patents

Composiciones terapéuticas y procedimientos que implican la transfección de ARNm Download PDF

Info

Publication number
ES2738315T3
ES2738315T3 ES14738078T ES14738078T ES2738315T3 ES 2738315 T3 ES2738315 T3 ES 2738315T3 ES 14738078 T ES14738078 T ES 14738078T ES 14738078 T ES14738078 T ES 14738078T ES 2738315 T3 ES2738315 T3 ES 2738315T3
Authority
ES
Spain
Prior art keywords
mrna
cells
cell
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14738078T
Other languages
English (en)
Spanish (es)
Inventor
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2738315T3 publication Critical patent/ES2738315T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES14738078T 2013-01-11 2014-01-10 Composiciones terapéuticas y procedimientos que implican la transfección de ARNm Active ES2738315T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Publications (1)

Publication Number Publication Date
ES2738315T3 true ES2738315T3 (es) 2020-01-21

Family

ID=51167392

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14738078T Active ES2738315T3 (es) 2013-01-11 2014-01-10 Composiciones terapéuticas y procedimientos que implican la transfección de ARNm

Country Status (13)

Country Link
US (3) US20150344537A1 (enExample)
EP (2) EP3501551B1 (enExample)
JP (4) JP2016511230A (enExample)
KR (2) KR102056511B1 (enExample)
CN (1) CN105473163A (enExample)
AU (1) AU2014205298B2 (enExample)
CA (2) CA3152721A1 (enExample)
ES (1) ES2738315T3 (enExample)
IL (2) IL239898B (enExample)
NZ (1) NZ710495A (enExample)
PL (1) PL2943226T3 (enExample)
SG (2) SG10201603946PA (enExample)
WO (1) WO2014110366A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102056511B1 (ko) * 2013-01-11 2019-12-16 마크 씨 허즈버그 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법
CA3040359A1 (en) 2016-11-07 2018-05-11 Westfalische Wilhelms-Universitat Munster S100a8/s100a9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
WO2001023002A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7754676B2 (en) * 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
WO2004089292A2 (en) * 2003-04-04 2004-10-21 The Regents Of The University Of California Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
DE12722942T1 (de) * 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
KR102056511B1 (ko) * 2013-01-11 2019-12-16 마크 씨 허즈버그 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법

Also Published As

Publication number Publication date
IL262252B (en) 2020-06-30
CN105473163A (zh) 2016-04-06
AU2014205298B2 (en) 2018-11-01
KR102056511B1 (ko) 2019-12-16
JP6956059B2 (ja) 2021-10-27
US20200231640A1 (en) 2020-07-23
EP2943226A1 (en) 2015-11-18
IL239898A0 (en) 2015-08-31
JP2017052781A (ja) 2017-03-16
US11912744B2 (en) 2024-02-27
CA2901409A1 (en) 2014-07-17
NZ710495A (en) 2019-10-25
JP6473729B2 (ja) 2019-02-20
EP2943226A4 (en) 2016-11-23
EP3501551B1 (en) 2023-06-07
CA3152721A1 (en) 2014-07-17
KR20180026811A (ko) 2018-03-13
KR20160031999A (ko) 2016-03-23
PL2943226T3 (pl) 2019-09-30
KR102119985B1 (ko) 2020-06-05
US12448421B2 (en) 2025-10-21
EP2943226B1 (en) 2019-03-13
EP3501551C0 (en) 2023-06-07
JP2019031521A (ja) 2019-02-28
JP2021019644A (ja) 2021-02-18
US20150344537A1 (en) 2015-12-03
SG11201505431XA (en) 2015-08-28
IL262252A (en) 2018-11-29
IL239898B (en) 2018-10-31
WO2014110366A1 (en) 2014-07-17
JP2016511230A (ja) 2016-04-14
EP3501551A1 (en) 2019-06-26
AU2014205298A1 (en) 2015-08-13
SG10201603946PA (en) 2016-07-28
US20240166701A1 (en) 2024-05-23
CA2901409C (en) 2022-06-07

Similar Documents

Publication Publication Date Title
US12448421B2 (en) Non-transgene transfection for therapeutic purposes
ES2869901T3 (es) Agentes inmunosupresores y su uso en terapia
WO2013152041A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
Raudenska et al. Caveolin‐1 in oncogenic metabolic symbiosis
ES2702618B2 (es) Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
Sha et al. One arrow two eagles: Multifunctional nano-system for macrophage reprogramming and osteoclastogenesis inhibition against inflammatory osteolysis
ES2863773T3 (es) Métodos y composiciones para prevenir o tratar el cáncer
EP3897669A1 (en) Methods and compositions related to therapeutic peptides for cancer therapy
Ye et al. Dendritic cells infected with recombinant adenoviral vector encoding mouse fibroblast activation protein‐α and human livin α exert an antitumor effect against Lewis lung carcinoma in mice
Gajewski Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy
ES2948443T3 (es) Modulación de la ciliogénesis
KR101848106B1 (ko) Gkn2를 유효성분으로 포함하는 항암 보조제
WO2024064879A2 (en) Interferon lambda (ifnl) inhibition in intestinal epithelial cells for treating inflammation
WO2025166631A1 (zh) Tmed10作为靶点在治疗炎症中的应用
US9885044B2 (en) Polynucleotides and methods for inhibiting cancer cells
EP4526456A2 (en) Use of engineered jurona virus (jurv) as an oncolytic virus platform for human cancers
ES2860850A1 (es) Agentes antivirales para el coronavirus
Liu et al. In Vitro and In Vivo Tissue Specific Cytotoxicity of Gastric Cancer Cells Resulting from CD: UPRT/5-FC Gene Therapy System Driven by hTERT Promoter
Wang et al. Genome-wide CRISPR/Cas9 screen identified MCL1 as a senolytic target for clearing palbociclib-induced senescent and PD-L1-positive cells in colorectal cancer